CRDF — Cardiff Oncology Share News
0.000.00%
Last trade - 00:00- $70.58m
- $34.93m
- $0.59m
Brief: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cardiff Oncology Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Cardiff Oncology Files For Mixed Shelf Of Up To $400 Million – SEC Filing
Cardiff Oncology Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-CoreCivic, Alphabet, Vail Resorts
U.S. STOCKS ON THE MOVE-CleanSpark, MoneyLion, CoreCivic
U.S. STOCKS ON THE MOVE-Boeing, Alaska Air, Centene
Cardiff Oncology rises on positive results from mid-stage cancer study
Brief: Cardiff Oncology Announces Positive Initial Data From First-Line RAS-mutated mCRC Clinical Trial
Brief: Cardiff Oncology Announces New Patent With Claims For Use Of Onvansertib In Treating KRAS Mutated mCRC
Cardiff Oncology Inc reports results for the quarter ended in September 30 - Earnings Summary
Cardiff Oncology Inc expected to post a loss of 27 cents a share - Earnings Preview
Cardiff Oncology Inc reports results for the quarter ended in June - Earnings Summary
Cardiff Oncology Inc expected to post a loss of 25 cents a share - Earnings Preview
Cardiff Oncology Inc reports results for the quarter ended in March - Earnings Summary
Cardiff Oncology Inc expected to post a loss of 25 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Broadcom, New York Community Bancorp, TopBuild
Cardiff Oncology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cardiff Oncology Provides Clinical Update On Phase 2 Randomized Second-Line ONSEMBLE Trial In Patients With RAS-mutated mCRC